
OBJ RELEASE



LIMITED

Quarterly Revenues for Wave I and Second Technology

OBJ Limited (ASX: OBJ) is pleased to provide an update regarding royalty and licensing revenues with its key Licensee.

OBJ has been informed that royalties from the Licensee for the March quarter, pertaining to skincare launches in Asia will be US\$94,290 (~A\$127,400). In addition OBJ has received, ahead of expectations, the first standstill and royalty fees for the second technology licensed to P&G, amounting to US\$125,000 (~A\$168,900).

Chairman Glyn Denison commented: "The royalties that our Licensee has reported includes the brief promotional period for Wave I products to coincide with Chinese New Year. It also includes the first introduction to the market of the sales of the second brand using Wave I. As already advised to the market, the Wave II products are due to be launched in Asia during the September quarter

It is also very pleasing that we have received the first standstill and royalty payments for the second technology ahead of our initial expectations. "

About OBJ

OBJ develops proprietary magnetic micro-array drug delivery and product enhancement technologies for the pharmaceutical, healthcare and consumer goods sectors. OBJ partners companies in the design and development of next generation products using physical science rather than chemistry to provide new levels of product performance without the cost of reformulation or new ingredient approvals.

OBJ offers a portfolio of proprietary technologies and supports partners by providing IPprotected market exclusivity, expertise in magnetic array design, feasibility and efficacy and claims testing, engineering and production.

About OBJ's Technologies

OBJ has developed a number of physical enhancement technologies based on the interactions between ingredient molecules and weak atomic forces. These influence the movement and penetration through the skin of drugs, active ingredients and formulations at the molecular level.

Complex 3-D magnetic fields produced by low cost microarrays or powdered electromagnetic inductors have the ability to repulse certain molecules to enhance diffusion and to alter the permeability of biological and non-biological targets.

OBJ's low cost micro-array film technology that utilise diamagnetic repulsion, induced permeation and energy redirection has already reached international markets to provide OBJ's Partners with a new way of managing the speed, depth of penetration and delivery of active ingredients in a wide range of pharmaceutical, healthcare and consumer products.

Directors

Mr Glyn Denison Mr Jeffrey Edwards Dr Chris Quirk

Company Secretary Mr John Palermo

Registered Office: 284 Oxford Street Leederville Western Australia 6007 Tel: +61 8 9443 3011 Fax: +61 8 9443 9960 www.obj.com.au ABN: 72 056 482 636

OBJ RELEASE

2 June 2017



Forward-looking Statements

This announcement contains certain "forward-looking statements" concerning OBJ. Where OBJ expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis.

Forward-looking statements provided in this announcement are based on assumptions and contingencies which are subject to change without notice. Such forward-looking statements including statements regarding intentions, planned events and potential results are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

There can be no assurance that actual outcomes will not differ materially from these forward-looking statements, and there are risks associated with OBJ and the industry which may affect the accuracy of the forward-looking statements. OBJ does not undertake any obligation to release publicly any revisions to any forward looking statement to reflect events or circumstances after the date of this announcement or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.

For more information:

Matthew Wright <u>matt@nwrcommunications.com.au</u> **Phone:** +61 451 896 420

Registered Office: 284 Oxford Street Leederville Western Australia 6007 Tel: +61 8 9443 3011 Fax: +61 8 9443 9960 www.obj.com.au ABN: 72 056 482 636